Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...
The first clinical consensus statement for managing multiple sclerosis (MS) in Australia and New Zealand has been released, ...
Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder ...
1don MSN
A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...
2don MSN
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...
The Balochistan government has introduced free treatment for breast cancer, Hemophilia A, Multiple Sclerosis, and Juvenile ...
According to Grand View Research, the global multiple sclerosis treatment market has been experiencing steady growth, driven by advancements in therapeutic options and a rising prevalence of the ...
ALS is a progressive neurodegenerative disease that currently has no cure. Commonly known as Lou Gehrig’s disease, ALS ...
Detailed price information for Cosmos Health Inc (COSM-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback